ANTI-COXIELLA BURNETII MOUSE MONOCLONAL

Added to your cart

ANTI-COXIELLA BURNETII MOUSE MONOCLONAL

Cart subtotal: £0.00

View cart (0) Checkout

#SKU BBI160

Get in touch to purchase this product

Contact our team of experts to discuss your requirements

Contact our expert team

Product Details

Coxiella refers to a genus of Gram-negative bacteria in the family Coxiellaceae. Coxiella burnetii is the only member of this genus. It is an obligate intracellular bacterial pathogen, and is the causative agent of Q fever. Q Fever is an infectious possible biological weapons agent that in its spore-like form is resistant to heat, pressure, drying and certain antiseptics. The Hybridoma cell line secreting this monoclonal antibody was generated at Dstl Porton Down (A UK Government Agency: Defence, Science and Technology Laboratory). This monoclonal antibody is manufactured and sold under licence from Ploughshare Innovations Ltd on behalf of the Secretary of State for Defence.
BBI160

More information

Attributes

Description

  • Shipping Information
  • Supply of these antibodies is subject to export control restrictions
  • Abbreviations
  • Coxiella
  • Preservatives
  • Sodium Azide
  • Storage
  • Store at -20°C, avoid repeat freeze- thaw cycles
  • Manufacturer Country
  • UK
  • Buffer
  • Phophate buffered saline, pH 7.4
  • Disease Area
  • Infectious Disease
  • Applications
  • Academic,Elisa, Lateral Flow
  • Clone Number
  • BBI160
  • Immunogen / Epitope
  • Coxiella Burnetii
  • Host
  • Mouse

Technical Documents

Product Information (154.75KB)

Sorry, no results found.

Enter the full lot number and hit enter.

BBI Solutions Brands

diarect.png

The acquisition of DIARECT in June 2020 and their world leading recombinant autoimmune antigen capability immediately enhances BBI’s portfolio and position as a ‘complete’ immunoassay reagent supplier. This further enhances BBI’s position as the world’s largest diagnostics components company with a market leading antigen portfolio.

mbs.png

Maine Biotechnology Services brings 27 years of knowledge, experience, process development, and project management to our customers to ensure the best possible antibodies for any application. As antibody development goals in the biotechnology and pharmaceutical industry have evolved the acquisition of MBS will help BBI further meet and exceed our customers needs.

Newsletter

Signup for our newsletter to receive the latest BBI Solutions updates and special offers in your inbox